TNXP · Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals disclosed preliminary financial results for the quarter ended March 31, 2026, showing a significant expansion in both revenue and operating losses. Net revenue from marketed products grew approximately 188% year-over-year to $6.9 million, primarily attributed to the initial contribution from TONMYA, which was launched in November 2025 and generated $3.7 million in sales. Revenue from the company's established products, Zembrace SymTouch and Tosymra, also increased to $3.2 million from $2.4 million in the prior year period. Despite the top-line growth, the company's net loss widened substantially to $40.8 million from $16.8 million in the same quarter of 2025. This deterioration in profitability was mirrored by a sharp increase in net cash used in operating activities, which rose to $40.2 million from $16.6 million year-over-year. Capital expenditures also increased to $1.7 million. The company reported a cash position of approximately $185.5 million as of March 31, 2026. Management indicated that this cash balance, supplemented by $17.4 million in net proceeds from equity offerings raised in the second quarter of 2026, is expected to fund planned operating and capital expenditure requirements into the second quarter of 2027. The company expects to file its Quarterly Report on Form 10-Q on or about May 11, 2026. All disclosed financial figures are preliminary, unaudited, and subject to revision pending the completion of quarter-end closing procedures.